Loading insider details...
Beta
Latest Form 4 (Jun 13, 2026): Sale of 3,355 SPRY shares, $33.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 13, 2026 | ARS Pharmaceuticals, Inc. (SPRY) | Sale | 3,355 | $33.5K |
| Jan 5, 2026 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 240,000 | n/a |
| May 22, 2025 | ARS Pharmaceuticals, Inc. (SPRY) | Exercise/Conversion | 100,000 | $558.0K |
| Jan 3, 2025 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 152,300 | n/a |
| Jan 4, 2024 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 300,000 | n/a |
| Oct 2, 2023 | ARS Pharmaceuticals, Inc. (SPRY) | Purchase | 40,000 | $145.0K |
| Jan 5, 2023 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 700,000 | n/a |
| Feb 23, 2022 | Evofem Biosciences, Inc. (EVFM) | Grant/Award | 300,000 | n/a |
| Jan 4, 2022 | Evofem Biosciences, Inc. (EVFM) | Disposition to Issuer | 120,000 | n/a |
| Dec 20, 2021 | Evofem Biosciences, Inc. (EVFM) | Purchase | 25,000 | $9.7K |